{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679252203136.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1254/fpj.143.144"}},{"identifier":{"@type":"COI","@value":"1:STN:280:DC%2BC2crhslKqtQ%3D%3D"}},{"identifier":{"@type":"PMID","@value":"24614638"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/fpj/143/3/143_144/_pdf"}},{"identifier":{"@type":"NAID","@value":"130003391437"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@language":"en","@value":"Pharmacological properties and clinical efficacy of tetrabenazine （Choreazine<sup>®</sup>Tablets 12.5 mg）, a therapeutic agent for non-rhythmic involuntary movement"},{"@language":"ja","@value":"非律動性不随意運動治療薬テトラベナジン（コレアジン<sup>®</sup>錠12.5 mg）の薬理学的特性と臨床効果"},{"@value":"Pharmacological properties and clinical efficacy of tetrabenazine （Choreazine^|^#174;Tablets 12.5 mg）, a therapeutic agent for non-rhythmic involuntary movement"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"ja","@value":"テトラベナジン（TBZ）はモノアミン小胞トランスポーター（VMAT）のタイプ2（VMAT2）選択的阻害薬であり，中枢神経のVMAT2を強力に阻害し，モノアミン（ドパミン（DA），ノルアドレナリン（NA），セロトニン（5-HT））性神経伝達を減弱する．TBZは生体に投与された後，初回通過効果により，α-およびβ-ジヒドロテトラベナジン（HTBZ）の2種類の異性体に代謝されるが，TBZ，α-およびβ-HTBZは同等のVMAT2阻害活性を有することから，未変化体または代謝物の形で効力を発揮すると考えられる．TBZは，ラット脳内（線条体等）のモノアミン量を速やかに減少させ，その作用にはDA選択性が認められた．この作用は投与後15分で最大となり，2時間持続した．また，TBZのモノアミン涸渇作用には耐薬性が生じ難かった．ハンチントン病（Huntington’s disease：HD）患者の初期症状の一つである舞踏運動等の不随意運動は，大脳基底核の「直接路優位」（ドパミンD<sub>1</sub>（D<sub>1</sub>）受容体機能亢進）により誘発されると推察され，TBZはD<sub>1</sub>受容体機能の抑制により，効力を発現すると考えられる．TBZはHDモデル動物においても有効性を示した．TBZはヒト肝臓でα-およびβ-HTBZに代謝され，その後9-および10-デスメチルα-HTBZ，9-および10-デスメチルβ-HTBZへ代謝されると推定された．健康成人にTBZを単回経口投与した場合，活性代謝物であるα-HTBZおよびβ-HTBZ並びに主要代謝物である9-デスメチルβ-HTBZの血漿中濃度は，投与後2時間以内に最高血漿中濃度（C<sub>max</sub>）に達し，曝露量には用量直線性が認められた．一方，TBZの血漿中濃度は低く推移し，投与後4時間以降はほとんど血漿中からは検出されなかった．国内外でHD患者を対象として実施された第III相臨床試験では，TBZ投与により舞踏運動合計スコア（TCS）の有意な改善が認められ，長期投与においてその改善効果は維持された．以上のように，これまで国内においてはHDを適応とする治療薬はなかったが，TBZはHDに伴う舞踏運動の適応症を有する国内で唯一の治療薬としてHD患者の生活の質（quality of life：QOL）改善に役立つことが期待される．"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410572171916217472","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000243879756"}],"foaf:name":[{"@language":"en","@value":"Machida Kouichi"},{"@language":"ja","@value":"町田 幸一"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"アルフレッサ ファーマ株式会社 医薬研究開発部 医薬研究室"}]},{"@id":"https://cir.nii.ac.jp/crid/1410572171916217473","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000243879757"}],"foaf:name":[{"@language":"en","@value":"Kawakami Daisuke"},{"@language":"ja","@value":"川上 大輔"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"アルフレッサ ファーマ株式会社 医薬研究開発部 東京開発室"}]},{"@id":"https://cir.nii.ac.jp/crid/1410572171916217474","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000243879758"}],"foaf:name":[{"@language":"en","@value":"Miki Masuo"},{"@language":"ja","@value":"三木 益生"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"アルフレッサ ファーマ株式会社 医薬研究開発部"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00155691"},{"@type":"EISSN","@value":"13478397"}],"prism:publicationName":[{"@language":"en","@value":"Folia Pharmacologica Japonica"},{"@language":"ja","@value":"日本薬理学雑誌"},{"@language":"en","@value":"Folia Pharmacol. Jpn."},{"@language":"ja","@value":"日薬理誌"},{"@language":"en","@value":"Folia Pharmacologica Japonica"},{"@language":"ja","@value":"日本薬理学雑誌"}],"dc:publisher":[{"@language":"en","@value":"The Japanese Pharmacological Society"},{"@language":"ja","@value":"公益社団法人 日本薬理学会"}],"prism:publicationDate":"2014","prism:volume":"143","prism:number":"3","prism:startingPage":"144","prism:endingPage":"151"},"reviewed":"false","url":[{"@id":"https://www.jstage.jst.go.jp/article/fpj/143/3/143_144/_pdf"}],"availableAt":"2014","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=%E3%83%86%E3%83%88%E3%83%A9%E3%83%99%E3%83%8A%E3%82%B8%E3%83%B3","dc:title":"テトラベナジン"},{"@id":"https://cir.nii.ac.jp/all?q=%E4%B8%8D%E9%9A%8F%E6%84%8F%E9%81%8B%E5%8B%95","dc:title":"不随意運動"},{"@id":"https://cir.nii.ac.jp/all?q=%E3%83%A2%E3%83%8E%E3%82%A2%E3%83%9F%E3%83%B3%E5%B0%8F%E8%83%9E%E3%83%88%E3%83%A9%E3%83%B3%E3%82%B9%E3%83%9D%E3%83%BC%E3%82%BF%E3%83%BC%E3%82%BF%E3%82%A4%E3%83%972","dc:title":"モノアミン小胞トランスポータータイプ2"},{"@id":"https://cir.nii.ac.jp/all?q=%E3%83%8F%E3%83%B3%E3%83%81%E3%83%B3%E3%83%88%E3%83%B3%E7%97%85%EF%BC%88Huntington%E2%80%99s%20disease%EF%BC%89","dc:title":"ハンチントン病（Huntington’s disease）"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360292618919918464","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620452246400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter."}]},{"@id":"https://cir.nii.ac.jp/crid/1360298341757063936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine."}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094896095232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recherches internationales sur l'histoire de l'éducation de la petite enfance"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096532888960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Differential Electrophysiological Changes in Striatal Output Neurons in Huntington's Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569870899712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570120714624","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Dihydrotetrabenazine Binding and Monoamine Uptake in Mouse Brain Regions"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570659179520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Therapeutics development for triplet repeat expansion diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045755357056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Huntington's disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519946432512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[<sup>11</sup>C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520303274368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"In vivo imaging of monoaminergic nerve terminals in normal and MPTP‐lesioned primate brain using positron emission tomography (PET) and [<sup>11</sup>C]tetrabenazine"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520815977216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994113225984","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reactivity of Aryldimesitylboranes under Suzuki−Miyaura Coupling Conditions"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994951566720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469325291776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tetrabenazine has properties of a dopamine receptor antagonist"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943980990080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diseases of Unstable Repeat Expansion: Mechanisms and Common Principles"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944145259520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tetrabenazine-induced depletion of brain monoamines: Characterization and interaction with selected antidepressants"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368236445184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tetrabenazine as antichorea therapy in Huntington disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319298945024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"In vivo binding of [11C]tetrabenazine to vesicular monoamine transporters in mouse brain"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794027378048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795406939520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Actionnaires, dirigeants financiers et managers. Historique et perspectives"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:1002930327"},{"@type":"CROSSREF","@value":"10.1254/fpj.143.144"},{"@type":"PUBMED","@value":"24614638"},{"@type":"CIA","@value":"130003391437"}]}